Vanda Pharmaceuticals Unveils Imsidolimab Data at EADV Meeting
Vanda Pharmaceuticals is presenting new clinical data on imsidolimab at the European Academy of Dermatology and Venereology Annual Meeting in Vienna. The findings, showcased through three distinct presentations, highlight the drug's efficacy in treating Generalized Pustular Psoriasis and its specific impact on inflammatory markers.
The company’s data highlights the therapeutic potential of imsidolimab, a fully humanized IgG4 monoclonal antibody designed to inhibit IL-36 receptor signaling. Among the findings presented are results from the GEMINI-1 study, which demonstrate the drug’s ability to reduce pustulation as measured by the Pustulation Rating Scale (Abstract ID: AS-2421, Poster P2806).
Additional presentations focus on the physiological impact of the treatment. Researchers detailed a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio (Abstract ID: AS-4323, Poster P1769), alongside an assessment of the drug’s immunogenicity (Abstract ID: AS-2420, Poster P1784). Vanda, which holds the exclusive global license for imsidolimab, expects patent and regulatory exclusivity for the orphan drug to remain in effect until the late 2030s.
Comments (0)
No comments yet. Be the first!